Tigis

Psychiatrie Supplementum 1/2020
Psychiatrie Supplementum 1/2020

Psychiatrie Supplementum 1/2020 (1)

úterý, 07 leden 2020 16:04

Psychiatrie Supplementum 1/2020

Napsal(a)

Suppl 1 20 obalka

62. ČESKO-SLOVENSKÁ
PSYCHOFARMAKOLOGICKÁ KONFERENCE
Farmakologie duše
Jeseník 15.–19. ledna 2020

 

OBSAH

EDITORIAL ............................................................................................................................. 1

OBSAH ................................................................................................................................... 2

PROGRAM ............................................................................................................................ 4

ODBORNÁ SYMPOZIA ......................................................................................................... 6
Nenaplněné potřeby v léčbě schizofrenie .............................................................................. 6
Mohou nové poznatky zlepšit účinnost
farmakoterapie psychických poruch? .................................................................................... 7
Fylogenetický vývoj neurotransmiterů –
mají neurotransmitery svůj vývoj a svou hierarchii? ............................................................. 9
Využití nových technologií v psychofarmakologickém výzkumu a léčbě ............................. 10
Možnosti terapie závislostí v České republice ..................................................................... 12
Sympozium Laboratoře neurostimulačních
metod PK 1. LF UK a VFN .................................................................................................. 13
Dáte si kávu nebo methylfenidát? aneb Mozkový doping u studentů ................................. 15
Chyby v psychofarmakologické léčbě ................................................................................. 16
Možnosti v léčbě hraniční poruchy osobnosti ..................................................................... 16
Vybrané aspekty léčby antidepresivy
(Sympozium Společnosti pro biologickou psychiatrii) ......................................................... 18
K translačnímu výzkumu rezistentní deprese ..................................................................... 20
Následky extrémního stresu u osob přeživších holokaust – 70 let poté ............................. 21
Dětská a dorostová psychiatrie ........................................................................................... 22
Druhý neuropsychiatrický pohár: kazuistický kvíz ............................................................... 23
Sympózium Slovenskej psychiatrickej spoločnosti .............................................................. 24
Ghrelin/GHS-R1A a jeho úloha v mechanismech závislostí a schizofrenie ......................... 25
Doporučené postupy versus denní praxe v léčbě demencí ................................................. 27
Dystonie na neurologicko-psychiatrickém pomezí ............................................................... 28
Ayahuaska: mezi pralesem a laboratoří ............................................................................... 28
Edukační dopoledne ČNPS: Léčba psychofarmaky 2019 .................................................... 29

WORKSHOPY ..................................................................................................................... 30
Sex, drogy a násilí – účinky Date Rape Drugs
a farmakologické zvládání agitovanosti a násilí ................................................................... 30
Porucha s bludy – psychoterapeutické vedení
a farmakoterapie .................................................................................................................. 30
Měřitelné projevy vnímání a aktivity u poruch příjmu potravy
a možnosti jejich terapeutického ovlivnění............................................................................ 31
Deset statečných – Vyhýbavá porucha osobnosti ................................................................ 31
Poklesky v psychofarmakologické léčbě úzkostných a afektivních poruch .......................... 32
Skupinová kognitivně-behaviorální terapie a farmakoterapie
u pacientů s ADHD v dospělosti ........................................................................................... 33

NOVÝ VÝZKUM .................................................................................................................... 34

VÝVĚSKOVÁ SDĚLENÍ ....................................................................................................... 38
Klinická K1–K25 ................................................................................................................... 38
Preklinická P1–P19 .............................................................................................................. 49

REJSTŘÍK ............................................................................................................................ 58

POKYNY AUTORŮM ........................................................................................................... 61

 

 

CONTENTS

EDITORIAL ............................................................................................................................ 1

CONTENTS ........................................................................................................................... 2

PROGRAM ............................................................................................................................ 4

SCIENTIFIC SYMPOSIA ....................................................................................................... 6
Unmet needs in schizophrenia treatment .............................................................................. 6
Can new findings improve the effectiveness
of pharmacotherapy of mental disorders? ............................................................................. 7
Phylogenetic development of neurotransmitters –
Do neurotransmitters develop and do they have their hierarchy? ......................................... 9
Application of new technologies in psychopharmacological research and treatment .......... 10
Possibilities in therapy of addictions in the Czech Republic ................................................ 12
Symposium of the Laboratory of Neurostimulation Methods, First Faculty
of Medicine and General University Hospital in Prague ...................................................... 13
Would you like coffee or methylfenidate?
Brain doping in students ...................................................................................................... 15
Errors in psychopharmacological treatment ........................................................................ 16
Treatment options for borderline personality disorder ......................................................... 16
Selected aspects of treatment with antidepressants
(Symposium of the Society of Biological Psychiatry) .......................................................... 18
To the translational research of treatment resistant depression ......................................... 20
Life-long effects of surviving Holocaust – extreme stress 70 years later ............................ 21
Child and Adolescent Psychiatry ........................................................................................ 22
Second neuropsychiatric cup: case study quiz ................................................................... 23
Symposium of Slovak Psychiatric Association .................................................................... 24
Ghrelin/GHS-R1A and its role in mechanisms of addiction and schizophrenia .................. 25
Guidelines in comparison with daily practise in dementia’s treatment ............................... 27
Dystonia on neurological-psychiatric borderlands .............................................................. 28
Ayahuasca: between forest and laboratory ........................................................................ 28
Educational morning CNPS: Treatment of psychopharmaceuticals 2019 .......................... 29

WORKSHOPS .................................................................................................................... 30
Sex, Drugs and Violence – Effects of Date rape drugs
and pharmacological management of agitation and violence ............................................. 30
Delusional disorder – psychotherapy management
and pharmacotherapy ......................................................................................................... 30
Measurable manifestations of perception and activity in eating disorders
and possibilities of their influence by therapy ..................................................................... 31
The magnificent ten – Avoidant personality disorder .......................................................... 31
Lapses in psychopharmacological treatment of anxiety and affective disorders ................ 32
Group cognitive behavioral therapy and pharmacotherapy
in adult ADHD patients ....................................................................................................... 33

NEW RESEARCH .............................................................................................................. 34

POSTERS .......................................................................................................................... 38
Clinical K1–K25 .................................................................................................................. 38
Preclinical P1–P19 ............................................................................................................. 49

INDEX ................................................................................................................................ 58

INSTRUCTION FOR AUTHORS ....................................................................................... 61